Iran has commissioned its first domestically produced 3.5-MW magnetic-bearing turboexpander at South Pars, marking a major engineering milestone and strengthening technological self-reliance, industrial resilience, and energy security.

By developing the Oncopore G2121, a domestically-produced electrochemotherapy (ECT) system featuring proprietary probe technology with no foreign analogues, Iran has joined the United Kingdom and Italy as one of only three nations worldwide capable of manufacturing this advanced cancer treatment device.

Iran's Martyr Soleimani Constellation, a 24-satellite narrowband IoT network, is set for launch beginning early 2027, showcasing the country's indigenous space technology, industrial-scale production, and strategic autonomy in space-based communications.

Iran joins elite ADC-producing countries with Tederox and Padynex, cutting costs by over 90 percent, expanding HER2-positive cancer treatment access, and showcasing rapid biopharmaceutical advancement despite sanctions.

Iran ranks fourth globally in high-impact research on advanced aircraft engines, including hypersonic propulsion, reflecting a focused, sanctions-resistant scientific strategy that has positioned it ahead of several traditional aerospace powers.

Iran Cancer Institute in Tehran has become West Asia’s largest cancer hospital, combining advanced treatment, research, education, and cutting-edge technologies while significantly expanding Iran’s regional and global standing in comprehensive cancer care and medical innovation.

Iran’s domestically developed ProSPECT II cardiac SPECT scanner has positioned it among a select group of countries capable of manufacturing advanced nuclear imaging systems, offering world-class diagnostic performance, lower costs, rapid servicing, and proven clinical reliability.